PCOS has no FDA-approved treatments? Not quite right

What did @baethiccc actually say?

Honestly? Not much, medically speaking. The transcript captured is song lyrics, not health commentary. The actual claims come from the caption: that PCOS is the "number one metabolic disorder in women" and has "zero FDA approved treatments." Those two sentences are doing a lot of heavy lifting for a video with nearly 10,000 views, so they deserve a serious look.

The caption framing is provocative and clearly designed to stoke frustration, which is understandable given how genuinely underfunded and mismanaged PCOS care has been historically. But provocative framing and accurate framing are not the same thing.

Does the science back this up?

Partially, and the part that holds up is the more damning one. PCOS affects an estimated 8 to 13 percent of reproductive-age women globally, making it the most common endocrine disorder in that population (Teede et al., 2023, Nature Reviews Endocrinology). Whether it earns the specific label of "number one metabolic disorder" depends on how you define metabolic disorder, but the disorder's scope is real and well-documented.

The FDA approval claim is more complicated. It is technically true that no drug has been FDA-approved specifically for PCOS as an indication. The FDA has approved oral contraceptives for certain PCOS-related symptoms, including irregular cycles and hyperandrogenism, and spironolactone sees heavy off-label use for androgen-related symptoms. Metformin, widely used for PCOS-related insulin resistance, is approved for type 2 diabetes, not PCOS. So the claim is true in a narrow technical sense but misleading without that context.

What did they get wrong (or right)?

They got the frustration right. The regulatory gap around PCOS is a legitimate public health problem. A 2023 review in the Journal of Clinical Endocrinology and Metabolism noted that clinical trial enrollment for PCOS-specific interventions has lagged significantly behind the disorder's prevalence (Dokras et al., 2023).

What the caption gets wrong, or at least leaves dangerously incomplete, is the implication that women with PCOS have no approved treatment options at all. That is not accurate. Multiple FDA-approved drugs are used in PCOS management under existing indications. Clomiphene citrate is FDA-approved for ovulation induction. Letrozole is widely used off-label for the same purpose with strong evidence behind it. Oral contraceptives carry FDA approval for hyperandrogenism management. Saying there are "zero" approved treatments erases real options that clinicians use every day, and could push people toward unvetted alternatives.

GLP-1 receptor agonists like semaglutide are increasingly studied for PCOS, particularly in patients with obesity and insulin resistance, but they are not approved for PCOS specifically. Calling them a solution without that caveat would be its own form of misinformation.

What should you actually know?

PCOS is real, underdiagnosed, and undertreated. The systemic failure to develop PCOS-specific approvals is worth being angry about. But the absence of a single drug approved solely for PCOS does not mean women are left without options. It means the options they have are borrowed from other indications, which creates real gaps in insurance coverage, clinical guidance, and patient advocacy.

If you have PCOS, the current evidence supports a combination approach: lifestyle modification, metformin for metabolic features, hormonal contraceptives for cycle regulation and androgen symptoms, and in some cases GLP-1 agonists for weight and insulin resistance when clinically appropriate. A 2023 international evidence-based guideline update (Teede et al., 2023) is the most current synthesis of what works. Talk to a clinician who actually knows PCOS management, because there is more available than this caption suggests.